ID   U3086MG
AC   CVCL_IR96
SY   U3086-MG; U3086
DR   cancercelllines; CVCL_IR96
DR   GEO; GSM1857606
DR   GEO; GSM1857822
DR   Progenetix; CVCL_IR96
DR   Wikidata; Q54973727
RX   PubMed=26629530;
RX   PubMed=27689322;
RX   PubMed=28122246;
WW   http://www.hgcc.se/
CC   Part of: Human Glioblastoma Cell Culture (HGCC) resource.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): PubMed=26629530
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 8,11
ST   D16S539: 11,14
ST   D18S51: 12,18
ST   D19S433: 13
ST   D21S11: 29,30
ST   D2S1338: 17,20
ST   D3S1358: 15,17
ST   D5S818: 11,14
ST   D7S820: 8,10
ST   D8S1179: 13,14
ST   FGA: 22
ST   TH01: 6,9.3
ST   TPOX: 8,12
ST   vWA: 16,17
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_IR94 ! U3084MG
SX   Male
AG   72Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 8
//
RX   PubMed=26629530; DOI=10.1016/j.ebiom.2015.08.026;
RA   Xie Y., Bergstrom T., Jiang Y.-W., Johansson P., Marinescu V.D.,
RA   Lindberg N., Segerman A., Wicher G., Niklasson M., Baskaran S.,
RA   Sreedharan S., Everlien I., Kastemar M., Hermansson A., Elfineh L.,
RA   Libard S., Holland E.C., Hesselager G., Alafuzoff I., Westermark B.,
RA   Nelander S., Forsberg-Nilsson K., Uhrbom L.;
RT   "The Human Glioblastoma Cell Culture resource: validated cell models
RT   representing all molecular subtypes.";
RL   EBioMedicine 2:1351-1363(2015).
//
RX   PubMed=27689322; DOI=10.18632/oncotarget.12298;
RA   Schmidt L., Baskaran S., Johansson P., Padhan N., Matuszewski D.J.,
RA   Green L.C., Elfineh L., Wee S.-M., Haggblad M., Martens U.,
RA   Westermark B., Forsberg-Nilsson K., Uhrbom L., Claesson-Welsh L.,
RA   Andang M., Sintorn I.-M., Lundgren B., Lonnstedt I., Krona C.,
RA   Nelander S.;
RT   "Case-specific potentiation of glioblastoma drugs by pterostilbene.";
RL   Oncotarget 7:73200-73215(2016).
//
RX   PubMed=28122246; DOI=10.1016/j.celrep.2017.01.003;
RA   Jiang Y.-W., Marinescu V.D., Xie Y., Jarvius M., Maturi N.P.,
RA   Haglund C., Olofsson S., Lindberg N., Olofsson T., Leijonmarck C.,
RA   Hesselager G., Alafuzoff I., Fryknas M., Larsson R., Nelander S.,
RA   Uhrbom L.;
RT   "Glioblastoma cell malignancy and drug sensitivity are affected by the
RT   cell of origin.";
RL   Cell Rep. 18:977-990(2017).
//